The Small Interfering RNA (siRNA) Therapeutics Market Size is valued at USD 1.6 Bn in 2023 and is predicted to reach USD 4.89 Bn by the year 2031 at a 15.0% CAGR during the forecast period for 2024-2031.
Small interfering RNA (siRNA) therapeutics describe a group of medicinal interventions that target disease-causing genes using small, engineered RNA molecules. Market expansion for siRNA treatments is driven by rising demand for precision medicine, new delivery platforms, and our increasing molecular understanding of disease causes. In addition, the increasing occurrence of chronic diseases presents numerous opportunities for creating and commercializing treatments based on small interfering RNAs.
Furthermore, market expansions are being propelled by the development of novel therapies, which in turn are being supported by rising investments in research initiatives from governments, private organizations, and pharmaceutical companies. In addition, the market of siRNA therapies is rising due to rising patient consciousness and the need for more precise, individualized treatments.
However, the market growth is hampered by the strict regulatory criteria of small interfering RNA (siRNA) therapeutics, therapies that can be expensive, and lengthy approval procedures for novel therapies, which are compounded by technical problems and obstacles to market expansion. In addition, because of the growing consensus among regulatory bodies regarding the therapeutic value of cancer, promising medications are being expedited through the review and approval processes, driving market growth. Furthermore, factors driving market expansion include an uptick in cancer HIV cases globally and a surge in research and development efforts related to creating these medications. Small interfering RNA therapeutics are in high demand because tumours, hereditary diseases, and viruses are on the rise worldwide.
The small interfering RNA (siRNA) therapeutics market is segmented based on product type, delivery methods, indication, route of administration (RoA) and End-User. The Delivery segment includes Lipid Nanoparticles (LNPs), Conjugates. According to the Indication segment, the market includes Hereditary Transthyretin-mediated Amyloidosis, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1, Primary Hypercholesterolemia, Others. By RoA, the segmentation comprises Intravenous (IV) and Subcutaneous.
The lipid nanoparticle (LNPs) in small interfering RNA (siRNA) therapeutics market is expected to hold a major global market share owing to its capacity to improve the stability and transport of siRNA molecules.
The North American small interfering RNA (siRNA) therapeutics market is expected to report the biggest market share in revenue in the near future. It can be attributed to the heavy financial backing for pharmaceutical and biotech research, a well-developed healthcare system, and the headquarters of prominent pharmaceutical corporations. There is a high incidence of chronic diseases, helpful legislative frameworks, and substantial public financing for small interfering RNA treatment methods, which is growing the region's growth. In addition, Asia Pacific is estimated to grow very fast in the global small interfering RNA (siRNA) therapeutics market because of the big population and increasing requirement of high-quality healthcare in the region, and the increasing awareness of advanced treatment alternatives is driving the fast growth of the siRNA therapeutics industry in the Asia Pacific region.
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 1.6 Bn |
| Revenue Forecast In 2031 | USD 4.89 Bn |
| Growth Rate CAGR | CAGR of 15.0% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product type, Delivery methods, Indication, route of administration (RoA) and end-user |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Alnylam, Silence Therapeutics, Silenseed Ltd, Sylentis, S.A., Sanofi Genzyme, Quark Pharmaceuticals, Dicerna Pharmaceuticals, Arrowhead Pharmaceuticals, Novartis, Novo Nordisk, Johnson & Johnson company, GSK, Aro Biotherapeutics and Other Market Players |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Small Interfering RNA (siRNA) Therapeutics Market By Product Type-
Small Interfering RNA (siRNA) Therapeutics Market By Delivery Methods-
Small Interfering RNA (siRNA) Therapeutics Market By Indication-
Small Interfering RNA (siRNA) Therapeutics Market By RoA-
Small Interfering RNA (siRNA) Therapeutics Market By End-User-
Small Interfering RNA (siRNA) Therapeutics Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.